Background: The therapeutic efficacy of using many medications simultaneously is frequently increased, although some combinations might cause undesirable drug-drug interactions (DDIs). Due to the lack of new clinical signs and symptoms and the frequent worsening of previously present illnesses, most interactions are missed by doctors. To stop the harmful effects of interactions, it is essential to quantify the frequency of probable DDIs. Objectives: To assess the prevalence and risk factors for patients' potential drug-drug interactions (pDDIs). To assess the variation in cash costs of the most commonly recommended generic drugs in dermatology and analyze the expense and prescription trends in the outpatient dermatology section. (OPD) Material and Method: A cross-sectional, descriptive, observational study was used in the investigation. The research was conduct from September 2022 to March 2023, and all data will be gathered by the end of March 2023. A total of 500 prescriptions were gathered. The data covered every patient who had a skin condition. Software called Lexicomp was used to assess DDI. All of the patients had skin diseases, either by itself or in combination with other co-morbid illnesses. Result: Out of the 500 prescriptions that were gathered, we found that 202 had DDI in patients with skin diseases, and 28 interactions were seen in comorbid conditions. The interactions are shown in Type A 19 (9%), Type B 64 (32%), Type C 79(39%), Type D 24(12%), and Type X 16(8%) in patients with skin diseases. Type B 8 (29%), Type C 12(43%), Type D 6(21%), Type X 2(7%) in comorbid condition. Levocetirizine (212), clindamycin (141), ketoconazole (110), clobetasol (104), and benzoyl peroxide (67) were the drugs that were prescribed the most frequently to treat skin conditions. Conclusion: The study's conclusions demonstrated that patients had a significant prevalence of probable DDIs. Drug combinations that might cause major adverse drug reactions (DDIs) should not be recommended to patients by doctors without proper investigation.